HR+ eBC: LVI predicts worse survival in ODX-intermediate cases, Israeli study shows

  • Mutai R & al.
  • Oncology
  • 25 Sep 2018

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Lymphovascular invasion (LVI) predicts poorer 5-year OS in patients with hormone-receptor (HR)-positive early breast cancer (eBC) with intermediate recurrence scores on multigene Oncotype DX (ODX) molecular profiling.
  • LVI does not affect 5-year OS in patients with low- or high-risk ODX scores.

Why this matters

  • Patients with intermediate ODX scores are more frequently foregoing chemotherapy.
  • The results of this study, if confirmed by others, suggest clinicians should counsel patients with intermediate ODX scores not to forego chemotherapy.

Study design

  • Retrospective cohort (n=657) HR+ eBC patients who underwent testing for LVI and ODX.
  • Funding: None disclosed.

Key results

  • Median follow-up was 61.3 months.
  • LVI was found in 6% of cohort.
  • LVI+ (vs LVI) was not associated with ODX scores (P=.225).
  • LVI+ (vs LVI) patients had worse 5-year DFS (HR, 2.93; P=.04).
  • LVI+ (vs LVI) patients had worse 5-year OS if they had intermediate ODX scores (99% vs 100%, respectively; P=.04), but not if they had high or low ODX scores.

Limitations

  • Retrospective design.
  • Small number of LVI+ patients.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit